7M6D image
Entry Detail
PDB ID:
7M6D
Title:
Structure of the SARS-CoV-2 RBD in complex with neutralizing antibodies BG4-25 and CR3022
Biological Source:
PDB Version:
Deposition Date:
2021-03-25
Release Date:
2021-05-05
Method Details:
Experimental Method:
Resolution:
3.10 Å
R-Value Free:
0.25
R-Value Work:
0.21
R-Value Observed:
0.22
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:CR3022 Fab Heavy Chain
Chain IDs:A
Chain Length:225
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:CR3022 Fab Light Chain
Chain IDs:B
Chain Length:221
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Spike protein S1
Chain IDs:C
Chain Length:212
Number of Molecules:1
Biological Source:Severe acute respiratory syndrome coronavirus 2
Polymer Type:polypeptide(L)
Description:BG4-25 Fab Heavy Chain
Chain IDs:D (auth: H)
Chain Length:224
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:BG4-25 Fab Light Chain
Chain IDs:E (auth: L)
Chain Length:215
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation

Abstact

Monoclonal antibodies (mAbs) are a focus in vaccine and therapeutic design to counteract severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants. Here, we combined B cell sorting with single-cell VDJ and RNA sequencing (RNA-seq) and mAb structures to characterize B cell responses against SARS-CoV-2. We show that the SARS-CoV-2-specific B cell repertoire consists of transcriptionally distinct B cell populations with cells producing potently neutralizing antibodies (nAbs) localized in two clusters that resemble memory and activated B cells. Cryo-electron microscopy structures of selected nAbs from these two clusters complexed with SARS-CoV-2 spike trimers show recognition of various receptor-binding domain (RBD) epitopes. One of these mAbs, BG10-19, locks the spike trimer in a closed conformation to potently neutralize SARS-CoV-2, the recently arising mutants B.1.1.7 and B.1.351, and SARS-CoV and cross-reacts with heterologous RBDs. Together, our results characterize transcriptional differences among SARS-CoV-2-specific B cells and uncover cross-neutralizing Ab targets that will inform immunogen and therapeutic design against coronaviruses.

Legend

Protein

Chemical

Disease

Primary Citation of related structures